Angara Bio
Drugging RNA-binding proteins with precision chemistry.
Angara Bio is a discovery-stage biotechnology company developing small-molecule therapeutics targeting RNA-binding proteins (RBPs) - central regulators of gene expression with established roles in disease but have remained largely undruggable. Building on foundational research by scientific founder Ken Hsu (UT Austin), published in Nature Communications, Angara’s proprietary live-cell chemoproteomics platform uncovers functionally relevant, ligandable sites within RNA–protein complexes, creating new opportunities for small-molecule drug discovery.
Angara’s lead program in myotonic dystrophy type 1 (DM1) aims to restore normal RNA splicing by releasing a key splicing regulator from toxic repeat RNA. The company is leveraging its platform to develop additional therapeutics targeting disease-driving RBPs across multiple indications.